मिनोक्सिडिल के इंटरैक्शन

हम जिन FDA लेबल और फैक्ट शीट को इंडेक्स करते हैं, उनमें मिनोक्सिडिल (Loniten, Rogaine; वैसोडाइलेटर) के 192 इंटरैक्शन दर्ज हैं: 96 गंभीर, 73 मध्यम, 23 मामूली, और 0 ऐसे जिनमें लेबल बताता है कि कोई महत्वपूर्ण इंटरैक्शन नहीं है। नीचे की हर प्रविष्टि उस वाक्य को उद्धृत करती है जिस पर वह आधारित है। दवा का यह पेज एक शुरुआती बिंदु है, आपकी स्थिति के लिए कोई फ़ैसला नहीं।

लेबल से लिए गए इंटरैक्शन

गंभीर इंटरैक्शन (96)

  • Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • इंडापामाइडथायज़ाइड डाइयूरेटिकगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • इर्बेसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • इर्बेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • इसराडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एज़िलसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एटेनोलोलबीटा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एटेनोलोल और क्लोरथैलिडोनबीटा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एथाक्रिनिक एसिडलूप डाइयूरेटिकगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एनालाप्रिलACE इनहिबिटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एनालाप्रिलैटACE इनहिबिटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एप्टिफिबाटाइडएंटीप्लेटलेट दवागंभीर

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (एप्टिफिबाटाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एप्लेरेनोनएल्डोस्टेरोन एंटागोनिस्टगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एमिलोराइडपोटैशियम-स्पेयरिंग डाइयूरेटिकगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एम्लोडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एम्लोडिपिन और एटोरवास्टेटिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एम्लोडिपिन और ओल्मेसार्टनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एम्लोडिपिन और बेनाज़ेप्रिलडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एम्लोडिपिन और वाल्सार्टनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एलिस्किरेनएंटीहाइपरटेंसिव (ब्लड प्रेशर की दवा)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एसिटाज़ोलामाइडकार्बोनिक एनहाइड्रेज़ इनहिबिटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एसिब्यूटोलोलबीटा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • एस्मोलोलबीटा ब्लॉकरगंभीर

    Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • ओल्मेसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • ओल्मेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • ओल्मेसार्टन, एम्लोडिपिन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • कार्वेडिलोलबीटा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • कैंडेसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • कैंडेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • कैप्टोप्रिलACE इनहिबिटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • क्लोज़ापिनएंटीसाइकोटिकगंभीर

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (क्लोज़ापिन लेबल, बॉक्स्ड चेतावनी)

  • क्लोनिडिनअल्फा-एड्रीनर्जिक एगोनिस्टगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • क्लोरथैलिडोनथायज़ाइड डाइयूरेटिकगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • क्लोरोथायज़ाइडथायज़ाइड डाइयूरेटिकगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • क्विनाप्रिलACE इनहिबिटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • ग्वानफेसिनअल्फा-एड्रीनर्जिक एगोनिस्टगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • टिज़ानिडिनमसल रिलैक्सेंटगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • टिमोलोलबीटा ब्लॉकरगंभीर

    Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • टेराज़ोसिनअल्फा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • टेल्मिसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • टेल्मिसार्टन और एम्लोडिपिनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • टेल्मिसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • टैडालाफिलPDE5 इनहिबिटरगंभीर

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (टैडालाफिल लेबल, चेतावनियां और सावधानियां)

  • टॉरसेमाइडलूप डाइयूरेटिकगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • ट्रायमटेरिनपोटैशियम-स्पेयरिंग डाइयूरेटिकगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • ट्रायमटेरिन और हाइड्रोक्लोरोथायज़ाइडपोटैशियम-स्पेयरिंग डाइयूरेटिकगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • ट्रैंडोलाप्रिलACE इनहिबिटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • डिल्टियाज़ेमकैल्शियम चैनल ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • डॉक्साज़ोसिनअल्फा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • डोरज़ोलामाइड और टिमोलोलकार्बोनिक एनहाइड्रेज़ इनहिबिटरगंभीर

    Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • नाइट्रोप्रुसाइडवैसोडाइलेटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • नाडोलोलबीटा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • निकार्डिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • निफेडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • निसोल्डिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • नेबिवोलोलबीटा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • पिंडोलोलबीटा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • पेरिंडोप्रिलACE इनहिबिटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • प्राज़ोसिनअल्फा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • प्रोप्रानोलोलबीटा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • फेनोक्सीबेंज़ामिनअल्फा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • फेलोडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • फोसिनोप्रिलACE इनहिबिटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • फ्यूरोसेमाइडलूप डाइयूरेटिकगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • बिसोप्रोलोलबीटा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • बीटाक्सोलोलबीटा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • बुमेटेनाइडलूप डाइयूरेटिकगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • बेनाज़ेप्रिलACE इनहिबिटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • ब्रिमोनिडिन और टिमोलोलअल्फा-एड्रीनर्जिक एगोनिस्टगंभीर

    Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • मिथाइलडोपाएंटीहाइपरटेंसिव (ब्लड प्रेशर की दवा)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • मेकामाइलामिनएंटीहाइपरटेंसिव (ब्लड प्रेशर की दवा)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • मेटोप्रोलोलबीटा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • मेटोलाज़ोनथायज़ाइड डाइयूरेटिकगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • मोएक्सिप्रिलACE इनहिबिटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • रैमिप्रिलACE इनहिबिटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • लिसिनोप्रिलACE इनहिबिटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • लेबेटालोलबीटा ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • लोफेक्सिडिनअल्फा-एड्रीनर्जिक एगोनिस्टगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • लोसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • लोसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • वाल्सार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • वाल्सार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • वेरापामिलकैल्शियम चैनल ब्लॉकरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • सैक्यूबिट्रिल और वाल्सार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)गंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • सोटालोलबीटा ब्लॉकरगंभीर

    Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • स्पिरोनोलैक्टोनएल्डोस्टेरोन एंटागोनिस्टगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • स्पिरोनोलैक्टोन और हाइड्रोक्लोरोथायज़ाइडएल्डोस्टेरोन एंटागोनिस्टगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • हाइड्रालाज़िनवैसोडाइलेटरगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

  • हाइड्रोक्लोरोथायज़ाइडथायज़ाइड डाइयूरेटिकगंभीर

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

मध्यम इंटरैक्शन (73)

  • अल्फुज़ोसिनअल्फा ब्लॉकरमध्यम

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (अल्फुज़ोसिन लेबल, चेतावनियां और सावधानियां)

  • Intervention: During concomitant use of CALDOLOR with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (आइबुप्रोफेन लेबल, दवाओं के इंटरैक्शन)

  • Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

  • Drug Interactions The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators. (आइसोसॉर्बाइड डाइनाइट्रेट लेबल, दवाओं के इंटरैक्शन)

  • The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators. (आइसोसॉर्बाइड मोनोनाइट्रेट लेबल, दवाओं के इंटरैक्शन)

  • आर्मोडाफिनिलCNS स्टिमुलेंटमध्यम

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (आर्मोडाफिनिल लेबल, चेतावनियां और सावधानियां)

  • Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 ) (इंडोमेथासिन लेबल, दवाओं के इंटरैक्शन)

  • इलोपेरिडोनएंटीसाइकोटिकमध्यम

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (इलोपेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एटोमोक्सेटिननॉरएपिनेफ्रिन रीअपटेक इनहिबिटरमध्यम

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (एटोमोक्सेटिन लेबल, दवाओं के इंटरैक्शन)

  • एडेनोसिनएंटीएरिदमिकमध्यम

    Hypotension Adenosine injection is a potent peripheral vasodilator and can induce significant hypotension. (एडेनोसिन लेबल, चेतावनियां और सावधानियां)

  • एड्रेनालिनसिम्पैथोमिमेटिकमध्यम

    Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter. (एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (एपोएटिन अल्फा लेबल, चेतावनियां और सावधानियां)

  • एपोप्रोस्टेनोलप्रोस्टाग्लैंडिन एनालॉगमध्यम

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (एपोप्रोस्टेनोल लेबल, दवाओं के इंटरैक्शन)

  • एरिपिप्राज़ोलएंटीसाइकोटिकमध्यम

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (एरिपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

  • एवानाफिलPDE5 इनहिबिटरमध्यम

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (एवानाफिल लेबल, चेतावनियां और सावधानियां)

  • एसेनापिनएंटीसाइकोटिकमध्यम

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (एसेनापिन लेबल, चेतावनियां और सावधानियां)

  • Intervention: During concomitant use of OXAPROZIN CAPSULES with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see WARNINGS AND PRECAUTIONS (5.6) ]. (ऑक्साप्रोज़िन लेबल, दवाओं के इंटरैक्शन)

  • ओलैंज़ापिनएंटीसाइकोटिकमध्यम

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (ओलैंज़ापिन लेबल, चेतावनियां और सावधानियां)

  • ओलैंज़ापिन और फ्लुओक्सेटिनएंटीसाइकोटिकमध्यम

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (ओलैंज़ापिन और फ्लुओक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (कार्बिडोपा लेबल, दवाओं के इंटरैक्शन)

  • कार्बिडोपा और लेवोडोपाडोपामिनर्जिक दवामध्यम

    Antihypertensive drugs: May cause symptomatic postural hypotension. (कार्बिडोपा और लेवोडोपा लेबल, दवाओं के इंटरैक्शन)

  • कार्बिडोपा, लेवोडोपा और एंटाकैपोनडोपामिनर्जिक दवामध्यम

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (कार्बिडोपा, लेवोडोपा और एंटाकैपोन लेबल, दवाओं के इंटरैक्शन)

  • कैरिप्राज़िनएंटीसाइकोटिकमध्यम

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (कैरिप्राज़िन लेबल, चेतावनियां और सावधानियां)

  • क्वेटियापिनएंटीसाइकोटिकमध्यम

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (क्वेटियापिन लेबल, चेतावनियां और सावधानियां)

  • ज़िप्रासिडोनएंटीसाइकोटिकमध्यम

    Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (ज़िप्रासिडोन लेबल, चेतावनियां और सावधानियां)

  • टेस्टोस्टेरोनएंड्रोजनमध्यम

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (टेस्टोस्टेरोन लेबल, चेतावनियां और सावधानियां)

  • टैक्रोलिमसइम्यूनोसप्रेसेंटमध्यम

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (टैक्रोलिमस लेबल, चेतावनियां और सावधानियां)

  • ट्रैज़ोडोनएंटीडिप्रेसेंटमध्यम

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

  • डाइएथिलप्रोपियॉनCNS स्टिमुलेंटमध्यम

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (डाइएथिलप्रोपियॉन लेबल, दवाओं के इंटरैक्शन)

  • Intervention: During concomitant use of ZIPSOR with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (डाइक्लोफेनाक लेबल, दवाओं के इंटरैक्शन)

  • Intervention: During concomitant use of diclofenac sodium/misoprostol with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.7) ] . (डाइक्लोफेनाक और मिसोप्रोस्टोल लेबल, दवाओं के इंटरैक्शन)

  • The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (डुलोक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • डेक्समिथाइलफेनिडेटCNS स्टिमुलेंटमध्यम

    • Antihypertensive Drugs: Monitor blood pressure. (डेक्समिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

  • डेक्समेडेटोमिडिनअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    • Co-administration with Other Vasodilators or Negative Chronotropic Agents : Use with caution due to additive pharmacodynamic effects. (डेक्समेडेटोमिडिन लेबल, चेतावनियां और सावधानियां)

  • नाइट्रोग्लिसरीननाइट्रेटमध्यम

    Antihypertensives: Possible additive hypotensive effects. (नाइट्रोग्लिसरीन लेबल, दवाओं के इंटरैक्शन)

  • निमोडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (निमोडिपिन लेबल, दवाओं के इंटरैक्शन)

  • नियासिनमध्यम

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (नियासिन लेबल, दवाओं के इंटरैक्शन)

  • ( 5.3 Hepatotoxicity) Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (नेप्रोक्सेन लेबल, चेतावनियां और सावधानियां)

  • Intervention : During concomitant use of naproxen and esomeprazole magnesium delayed-release tablets with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.6) ]. (नेप्रोक्सेन और एसोमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

  • Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (पाइरोक्सिकैम लेबल, दवाओं के इंटरैक्शन)

  • Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (पाज़ोपैनिब लेबल, चेतावनियां और सावधानियां)

  • पेंटोक्सिफाइलिनमिथाइलज़ैंथिनमध्यम

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (पेंटोक्सिफाइलिन लेबल, दवाओं के इंटरैक्शन)

  • • Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (पैरासिटामोल और आइबुप्रोफेन लेबल, चेतावनियां और सावधानियां)

  • पैलिपेरिडोनएंटीसाइकोटिकमध्यम

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (पैलिपेरिडोन लेबल, चेतावनियां और सावधानियां)

  • फेनेलज़िनMAO इनहिबिटरमध्यम

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (फेनेलज़िन लेबल, चेतावनियां)

  • Intervention: During concomitant use of FENOPROFEN CALCIUM with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (फेनोप्रोफेन लेबल, दवाओं के इंटरैक्शन)

  • Intervention: During concomitant use of flurbiprofen with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5) ]. (फ्लर्बिप्रोफेन लेबल, दवाओं के इंटरैक्शन)

  • बेंज़फेटामाइनCNS स्टिमुलेंटमध्यम

    Amphetamines may decrease the hypotensive effect of antihypertensives. (बेंज़फेटामाइन लेबल, दवाओं के इंटरैक्शन)

  • Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (बोर्टेज़ोमिब लेबल, चेतावनियां और सावधानियां)

  • ब्रिमोनिडिनअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

  • ब्रेक्सपिप्राज़ोलएंटीसाइकोटिकमध्यम

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (ब्रोमफेनिरामिन, स्यूडोएफेड्रिन और डेक्सट्रोमेथॉर्फन लेबल, दवाओं के इंटरैक्शन)

  • ब्रोमोक्रिप्टिनडोपामिन एगोनिस्टमध्यम

    Use caution in patients taking antihypertensive medications. (ब्रोमोक्रिप्टिन लेबल, चेतावनियां और सावधानियां)

  • मिथाइलफेनिडेटCNS स्टिमुलेंटमध्यम

    Antihypertensive Drugs: Monitor blood pressure. (मिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

  • मिर्टाज़ापिनएंटीडिप्रेसेंटमध्यम

    REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (मिर्टाज़ापिन लेबल, चेतावनियां और सावधानियां)

  • Intervention: During concomitant use of mefenamic acid with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.6 )] . (मेफेनामिक एसिड लेबल, दवाओं के इंटरैक्शन)

  • Intervention: During concomitant use of QAMZOVA with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (मेलोक्सिकैम लेबल, दवाओं के इंटरैक्शन)

  • मोडाफिनिलCNS स्टिमुलेंटमध्यम

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (मोडाफिनिल लेबल, चेतावनियां और सावधानियां)

  • रियोसिगुआटवैसोडाइलेटरमध्यम

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (रियोसिगुआट लेबल, चेतावनियां और सावधानियां)

  • रिस्पेरिडोनएंटीसाइकोटिकमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • लुमाटेपेरोनएंटीसाइकोटिकमध्यम

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (लुमाटेपेरोन लेबल, चेतावनियां और सावधानियां)

  • ल्यूरासिडोनएंटीसाइकोटिकमध्यम

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (ल्यूरासिडोन लेबल, चेतावनियां और सावधानियां)

  • वार्डेनाफिलPDE5 इनहिबिटरमध्यम

    When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (वार्डेनाफिल लेबल, चेतावनियां और सावधानियां)

  • Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

  • साइक्लोबेंज़ाप्रिनमसल रिलैक्सेंटमध्यम

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (साइक्लोबेंज़ाप्रिन लेबल, दवाओं के इंटरैक्शन)

  • साइक्लोस्पोरिनइम्यूनोसप्रेसेंटमध्यम

    If hypertension persists, the dose of Neoral should be further reduced or blood pressure should be controlled with antihypertensive agents. (साइक्लोस्पोरिन लेबल, सावधानियां)

  • सिलोडोसिनअल्फा ब्लॉकरमध्यम

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (सिलोडोसिन लेबल, चेतावनियां और सावधानियां)

  • सिल्डेनाफिलPDE5 इनहिबिटरमध्यम

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (सिल्डेनाफिल लेबल, चेतावनियां और सावधानियां)

  • Initiate and/or adjust antihypertensive therapy as appropriate. (सुनिटिनिब लेबल, चेतावनियां और सावधानियां)

  • Monitor patients to assure diuretic efficacy including antihypertensive effects. (सुमाट्रिप्टान और नेप्रोक्सेन लेबल, दवाओं के इंटरैक्शन)

  • Intervention: During concomitant use of VYSCOXA with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5.6) ]. (सेलेकॉक्सिब लेबल, दवाओं के इंटरैक्शन)

  • Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (सोराफेनिब लेबल, चेतावनियां और सावधानियां)

  • During concomitant use of hydrocodone bitartrate and ibuprofen tablets with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects (see WARNINGS: Renal Toxicity and Hyperkalemia ). (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, दवाओं के इंटरैक्शन)

मामूली ज़िक्र (23)

  • इकाटिबेंटमामूली

    ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (इकाटिबेंट लेबल, दवाओं के इंटरैक्शन)

  • एटोडोलैकNSAIDमामूली

    Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (एटोडोलैक लेबल, दवाओं के इंटरैक्शन)

  • एफेड्रिनसिम्पैथोमिमेटिकमामूली

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (एफेड्रिन लेबल, दवाओं के इंटरैक्शन)

  • कीटोप्रोफेनNSAIDमामूली

    ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (कीटोप्रोफेन लेबल, चेतावनियां और सावधानियां)

  • कीटोरोलैकNSAIDमामूली

    Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists. (कीटोरोलैक लेबल, दवाओं के इंटरैक्शन)

  • क्लोरप्रोमाज़िनएंटीसाइकोटिकमामूली

    Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (क्लोरप्रोमाज़िन लेबल, चेतावनियां)

  • टैम्सुलोसिनअल्फा ब्लॉकरमामूली

    Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

  • टोल्मेटिनNSAIDमामूली

    DRUG INTERACTIONS ACE Inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE Inhibitors. (टोल्मेटिन लेबल, दवाओं के इंटरैक्शन)

  • ट्राइफ्लुओपेराज़िनएंटीसाइकोटिकमामूली

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (ट्राइफ्लुओपेराज़िन लेबल, सावधानियां)

  • Drug Interactions ACE-inhibitors and Angiotensin II Anagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (डाइफ्लुनिसाल लेबल, दवाओं के इंटरैक्शन)

  • डेक्सट्रोएम्फेटामाइनCNS स्टिमुलेंटमामूली

    Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

  • डेसिप्रामिनट्राइसाइक्लिक एंटीडिप्रेसेंटमामूली

    This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (डेसिप्रामिन लेबल, चेतावनियां)

  • If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (डेसोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, चेतावनियां)

  • ड्यूटास्टेराइड और टैम्सुलोसिन5-अल्फा रिडक्टेज़ इनहिबिटरमामूली

    Alpha-adrenergic antagonists and PDE-5 inhibitors are both vasodilators that can lower blood pressure. (ड्यूटास्टेराइड और टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

  • नैबुमेटोनNSAIDमामूली

    Drug Interactions: ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (नैबुमेटोन लेबल, दवाओं के इंटरैक्शन)

  • नॉरट्रिप्टिलीनट्राइसाइक्लिक एंटीडिप्रेसेंटमामूली

    The antihypertensive action of guanethidine and similar agents may be blocked. (नॉरट्रिप्टिलीन लेबल, चेतावनियां)

  • प्रोक्लोरपेराज़िनएंटीसाइकोटिकमामूली

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (प्रोक्लोरपेराज़िन लेबल, सावधानियां)

  • प्रोट्रिप्टिलीनट्राइसाइक्लिक एंटीडिप्रेसेंटमामूली

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (प्रोट्रिप्टिलीन लेबल, चेतावनियां)

  • ब्यूटॉर्फेनॉलओपिओइडमामूली

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (ब्यूटॉर्फेनॉल लेबल, चेतावनियां)

  • मेक्सिलेटिनएंटीएरिदमिकमामूली

    In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (मेक्सिलेटिन लेबल, दवाओं के इंटरैक्शन)

  • मेथोहेक्सिटलबार्बिट्यूरेटमामूली

    Post injury arterial injection of vasodilators and/or arterial infusion of parenteral fluids are generally regarded to be of no value in altering outcome. (मेथोहेक्सिटल लेबल, चेतावनियां)

  • साल्सालेटNSAIDमामूली

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (साल्सालेट लेबल, दवाओं के इंटरैक्शन)

  • सुलिंडैकNSAIDमामूली

    Drug Interactions ACE-Inhibitors and Angiotensin II Antagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (सुलिंडैक लेबल, दवाओं के इंटरैक्शन)

आप जो कुछ भी लेते हैं, उस सबके साथ मिनोक्सिडिल को जांचें। अपनी पूरी सूची जोड़ें; हर जोड़ी एक साथ जांची जाती है।

चेकर में खोलें

यह चिकित्सकीय सलाह नहीं है। गंभीरता लेबल के शब्दों को दर्शाती है, आपकी परिस्थितियों को नहीं। “गंभीर” चिह्न वाला संयोजन डॉक्टर की देखरेख में सामान्य बात हो सकता है, और “मामूली” चिह्न वाला संयोजन ऊंची खुराक पर मायने रख सकता है। फार्मासिस्ट से पूछें।